Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Carlyle Secured Lending Q1 2026 Earnings Call - Dividend Reset and JV Ramp Signal Earnings Trough
Carlyle Secured Lending reported a steady but pressured first quarter, marked by a dividend reset to $0.35 per share and a strategic pivot toward joint venture scaling. Management emphasized resilient...
- Dividend reset to $0.35 per share for Q2 2026, down from $0.40, reflecting current portfolio earnings power while maintaining supplemental dividend policy.
- New investment spreads widened by 50 basis points in Q1 2026, signaling a shift to a lender-friendly environment with tighter documentation.
- Earnings expected to trough in Q2 2026, with a rebound anticipated in Q3 as joint ventures begin to ramp.
- +7 more takeaways
PRA Group Q1 2026 Earnings Call - Cash Collections Surge 11% as Legal and Digital Channels Drive Operating Leverage
PRA Group delivered a strong Q1 2026 performance, with cash collections rising 11% year-over-year to $552 million and adjusted EBITDA up 14% to $1.3 billion over the last twelve months. The company’s ...
- Cash collections grew 11% year-over-year to $552 million, driven by U.S. legal and digital channels, with cash efficiency improving to 62%.
- Adjusted EBITDA for the last twelve months rose 14% to $1.3 billion, outpacing cash collection growth and signaling expanding operating leverage.
- Net leverage declined to 2.71x from 2.73x in Q4 2025, with a stated target to reach the mid-2x range over the next few years.
- +7 more takeaways
Arcus Biosciences Q1 2026 Earnings Call - Casdatifan Takes Center Stage as PEAK-1 Enrollment Accelerates
Arcus Biosciences is pivoting hard into a new era with full ownership of its lead asset, casdatifan, and a clear, multi-line strategy to dominate the kidney cancer market. The company announced accele...
- Arcus Biosciences has taken full ownership of its lead asset, casdatifan, and is now laser-focused on dominating the kidney cancer market with a multi-line development strategy.
- PEAK-1, the Phase III trial for casdatifan in the second-line setting, is enrolling rapidly with full enrollment targeted by the end of 2026.
- Management claims casdatifan has a superior pharmacodynamic profile and durability compared to competitor belzutifan, citing a 45% confirmed ORR in late-line monotherapy versus belzutifan's historical 22%.
- +9 more takeaways
Emerson Electric Q2 2026 Earnings Call - Software & Systems Driven by Power, AI Positioning Strengthens Amid Middle East Headwinds
Emerson Electric reported Q2 2026 results shaped by a 1-point sales headwind from the Middle East conflict, but underlying momentum remains robust. Software & Systems led with 18% underlying order gro...
- Underlying orders grew 5% in Q2 2026, with Software & Systems up 18%, driven by power, life sciences, and LNG.
- Test & Measurement surged 12%, led by semiconductors and aerospace & defense, with automotive expected to bottom out.
- Middle East conflict caused a 1-point sales headwind (~$50M in Q2), with $100M in rebuild opportunities expected over six quarters.
- +7 more takeaways
Integra LifeSciences Q1 2026 Earnings Call - CEO Returns, Revenue Beats, and Tariff Tailwinds
Integra LifeSciences delivered a strong first quarter, beating revenue and EPS guidance as returning supply and favorable tariff refunds lifted results. The company is raising its full-year adjusted E...
- CEO Transition: Stuart Essig has returned as CEO and Chairman, replacing Mojdeh Poul. He emphasized a renewed focus on commercial execution, customer alignment, and organizational culture, while affirming that existing transformation and compliance initiatives remain unchanged.
- Strong Q1 Results: Total revenue reached $392 million, up 2.4% reported and 1.3% organic. Adjusted EPS came in at $0.54, beating the high end of guidance by approximately $0.10, driven by revenue growth, favorable product mix, and tariff benefits.
- Guidance Update: The company is maintaining its 2026 revenue guidance of $1.66 billion-$1.70 billion but is raising full-year adjusted EPS guidance to $2.40-$2.50, up $0.10, reflecting a $0.02 per share benefit from IEEPA tariff refunds and improved operational performance.
- +7 more takeaways
TransMedics Q1 2026 Earnings Call - Aggressive Growth Investments and CHOPS Pivot Expand Addressable Market
TransMedics delivered a strong Q1 2026, with revenue growing 21% year-over-year to $174 million and adjusted operating profit of $18.1 million. The company is executing a deliberate, capital-intensive...
- Total revenue reached $174 million in Q1 2026, up 21% year-over-year and 8% sequentially, driven by strong liver performance and growing logistics services.
- U.S. transplant product revenue grew 22% year-over-year to $102 million, while international revenue surged 39% to $6 million, signaling early but meaningful global traction.
- Adjusted operating profit came in at $18.1 million, representing a 10.4% adjusted operating margin, with management citing near-term margin pressure due to strategic investments.
- +7 more takeaways
Latham Group Q1 2026 Earnings Call - Sand State Strategy Drives Fiberglass Growth Amid Macro Headwinds
Latham Group delivered a resilient start to 2026, posting 5% net sales growth to $117 million despite adverse weather and a flat U.S. pool start outlook. The quarter was defined by double-digit sales ...
- Net sales rose 5% year-over-year to $117 million, driven by 3% organic growth and a one-month contribution from the Freedom Pools acquisition.
- Gross margins expanded 220 basis points to 32%, fueled by volume leverage and ongoing lean manufacturing and value engineering initiatives.
- SG&A expenses jumped 20% to $37 million, reflecting strategic investments in sales, marketing, digital transformation, and $2.3 million in Coverstar Central earn-out costs.
- +7 more takeaways
"Veeco Q1 2026 Earnings Call - $250M Indium Phosphide Order Signals AI Optical Infrastructure Inflection
Veeco delivered a solid Q1 2026, with revenue of $158 million and non-GAAP EPS of $0.14, landing within guidance despite a modest gross margin dip to 36% from a single China-related LSA shipment delay...
- Q1 2026 revenue came in at $158 million, with non-GAAP diluted EPS of $0.14, both within management’s guidance range.
- Gross margin landed at 36%, slightly below the 37.7% prior quarter, largely due to a single $8 million LSA system shipment delay to a Chinese customer following new BIS licensing requirements.
- Veeco secured over $250 million in new orders for indium phosphide laser manufacturing equipment, driven by the industry transition from copper to optical interconnects in AI data centers.
- +10 more takeaways
FIGS Q1 2026 Earnings Call - Revenue Surges 28% as Active Customers Top 3 Million and Profitability Widens
FIGS delivered a powerhouse start to fiscal 2026, with net revenue jumping 28% year-over-year to $159.9 million and beating top-line expectations. The company crossed the 3 million active customer mil...
- Net revenue grew 28% year-over-year to $159.9 million, beating the low 20% growth guide.
- Active customers surpassed 3 million for the first time, with acquisition accelerating to 12% year-over-year.
- Adjusted EBITDA margin reached 8.7%, exceeding guidance by 170 basis points and up from 7.3% last year.
- +7 more takeaways
RadNet Inc Q1 2026 Earnings Call - Advanced Imaging Shift and Digital Health Acceleration Drive Record Revenue
RadNet delivered record first-quarter 2026 revenue and adjusted EBITDA, driven by a decisive industry shift toward advanced imaging and accelerating Digital Health integration. Despite an estimated $1...
- Record Q1 2026 Performance: Revenue grew 22.1% and adjusted EBITDA increased 36.3% year-over-year, setting new quarterly records despite an estimated $13 million revenue impact from severe East Coast weather.
- Margin Expansion: Reported adjusted EBITDA margins improved by 115 basis points. On a normalized basis, excluding weather and prior-year wildfire impacts, margins expanded by 52 basis points, reflecting operational efficiency.
- Advanced Imaging Dominance: Advanced imaging now represents 29.3% of procedural volume, up 235 basis points year-over-year. This segment drives over 60% of revenue despite being a smaller volume share, highlighting superior profitability.
- +7 more takeaways